Generation Bio Co. shares rise 1.65% intraday after Junshi Biosciences reports 49% revenue growth in H1 2025.

miércoles, 27 de agosto de 2025, 9:54 am ET1 min de lectura
GBIO--
Generation Bio Co. rose 1.65% in intraday trading, with the company's stock price movement aligning with the positive financial performance of Junshi Biosciences, a leading biopharmaceutical company. Junshi Biosciences reported a 49% increase in total revenue for the first half of 2025, driven mainly by pharmaceutical sales, with its core product, TUOYI® (toripalimab), contributing significantly to this growth.

Generation Bio Co. shares rise 1.65% intraday after Junshi Biosciences reports 49% revenue growth in H1 2025.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios